Search results for "Peritoneal Neoplasm"

showing 10 items of 48 documents

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

2013

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. Methods The study presented was a retrospective analysis of 50 gastrointestinal cancer patients treated with cetuximab in combination with either FOLFIRI or FOLFOX. One cohort of 15 patients received an in-house reactive skin protocol upon development of an exanthema. A second cohort of 15 patients received a skin prophylaxis starting with the first dose of cetuximab before clinical signs of toxicity. A third historic group o…

MaleCancer ResearchColorectal cancerAdministration TopicalAdministration OralCetuximabMinocyclineGastroenterologyPeritoneal NeoplasmPeritoneal NeoplasmsGastrointestinal NeoplasmsSkinHematologyintegumentary systemCetuximabTherapy reactiveMultimodal therapyVitamin K 1General MedicineMiddle AgedCombined Modality TherapyAnti-Bacterial AgentsSurvival RateTreatment OutcomeAppendiceal NeoplasmsOncologyColonic NeoplasmsAdenocarcinomaFemaleErratumQuinolizinesFluoroquinolonesmedicine.drugmedicine.medical_specialtyPrednisoloneEGFRDetergentsAntineoplastic AgentsAdenocarcinomaAntibodies Monoclonal HumanizedDisease-Free SurvivalMetronidazoleRashInternal medicineIntestinal NeoplasmsmedicineCombined Modality TherapyHumansSurvival rateAgedRetrospective StudiesOriginal PaperRectal Neoplasmsbusiness.industryRetrospective cohort studyAntibiotic ProphylaxisExanthemamedicine.diseaseDermatologydigestive system diseasesSurgerybusinessJournal of Cancer Research and Clinical Oncology
researchProduct

Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma - a Report of 2 Cases

2014

<b><i>Summary</i></b><b><i>Background: </i></b>Malignant ascites is a frequent complication in gastrointestinal malignancy and is unresponsive to systemic therapies. Therapeutic options are limited, and repeated paracentesis is associated with increased loss of fluids and proteins, and impaired quality of life. The bi-specific trifunctional antibody catumaxomab has been approved for the treatment of refractory ascites. It has been proposed that repeated application leads to formation of human anti-mouse antibodies with a decrease in effectiveness and potentially hypersensitivity reactions. <b><i>Case Report: </i></b>Her…

MaleCancer Researchmedicine.medical_specialtyCatumaxomabGastroenterologyStomach NeoplasmsInternal medicineAntibodies BispecificAscitesmedicineParacentesisCarcinomaHumansInfusions ParenteralPeritoneal Neoplasmsmedicine.diagnostic_testSignet ring cellbusiness.industryAscitesCancerHematologyMiddle Agedmedicine.diseaseTrifunctional antibodySurgeryOncologyRetreatmentFemalemedicine.symptomComplicationbusinessCarcinoma Signet Ring Cellmedicine.drugOncology Research and Treatment
researchProduct

Benign multicystic mesothelioma: A case report of recurrent disease in a young adult with familiarity for renal cell carcinoma

2019

Benign multi-cystic peritoneal mesothelioma (BMCM) is a very rare disease (about 150 cases observed). The aetiology is currently little-known, and the data collected, without having achieved conclusive re sults, identify two possible causes: neoplastic and reactive inflammatory. This case report refers to a recidivism of BCMC in a patient whose brother, few months before, underwent a left nephrectomy and right renal Radio Frequency Termo Ablation (RFTA) for bilateral papillary renal cell carcinoma. For the recurring trend, the onset in a male young patient without chronic inflammatory diseases evidence, the presence of a first degree relative with a rare carcinoma we supposed a neoplastic a…

MaleHumansMesothelioma CysticMiddle AgedNeoplasm Recurrence Localbenign multcystic mesotheliom renal cells kideny tumor familiarity oncologyCarcinoma Renal CellKidney NeoplasmsPeritoneal Neoplasms
researchProduct

Diffuse malignant biphasic peritoneal mesothelioma with cystic areas

2016

We report a case of peritoneal biphasic mesothelioma with cystic areas in a patient with professional exposure to asbestos. It showed focal epithelial glandular and papillary proliferations, also presenting fluid filled cysts, whose wall consisted of a proliferation of spindle cells. Atypia and mitoses were very scanty. EMA, vimentin, CK5/6, D2-40, calretinin and P53 were positive and desmin was negative in both epithelial and spindle areas, including the ones surrounding the cystic spaces. These findings gave an essential aid in the differential diagnosis with a benign cystic mesothelioma and with a cystic epithelial mesothelioma with secondary pseudosarcomatous myofibroblastic proliferati…

MaleMesotheliomaLung NeoplasmsMesothelioma MalignantAscitesAsbestosMesothelioma CysticPemetrexedSettore MED/08 - Anatomia PatologicaAppendicitisCystic Mesothelioma Immunohistochemistry Malignant Mesothelioma Peritoneal Diseases Mesothelial Neoplasms.Diagnosis DifferentialSettore MED/18 - Chirurgia GeneraleCrohn DiseaseOccupational ExposureAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorHumansCisplatinDiagnostic ErrorsPeritoneal NeoplasmsAged
researchProduct

Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer

2015

Modern chemotherapy aims to improve long-term survival for selected patients with peritoneal carcinomatosis. Publications suggest promising results, but the spread of these new aggressive treatment strategies in the general population is not well known.The aim of this study was to draw a picture of epidemiology, management, and survival in synchronous and metachronous peritoneal carcinomatosis from colorectal cancer.The cumulative risk of metachronous peritoneal carcinomatosis was estimated in patients resected for cure. Net survival rates were calculated for synchronous and metachronous peritoneal carcinomatosis.The study was conducted with the use of the Burgundy Digestive Cancer Registry…

MaleOncologymedicine.medical_specialtyColorectal cancerPopulationAntineoplastic AgentsAdenocarcinomaInternal medicineEpidemiologymedicineCarcinomaHumansRegistrieseducationSurvival ratePeritoneal NeoplasmsAgedRetrospective Studieseducation.field_of_studybusiness.industryCarcinomaGastroenterologyRetrospective cohort studyCytoreduction Surgical ProceduresGeneral MedicinePrognosismedicine.diseaseAdenocarcinoma MucinousSurvival RateAdenocarcinomaFemaleObservational studyFrancePeritoneumColorectal NeoplasmsbusinessDiseases of the Colon & Rectum
researchProduct

Therapy of Peritoneal Murine Cancer with Biological Response Modifiers

1985

We have used a murine renal adenocarcinoma of spontaneous origin (Renca) inplanted in the peritoneal cavity to study the therapeutic potential of biological response modifiers (BRMs) used alone or in conjunction with chemotherapy. This tumor model is therapeutically challenging since following intraperitoneal (i.p.) injection, the tumor grows progressively with hemorrhagic ascites, abdominal metastases to lymph nodes, liver, spleen, most serous membranes, and, in some animals, metastases to extra-abdominal sites (lungs). In the absence of therapy, death invariably occurs within 36 +/- 2 days. The tumor is efficiently lysed in 4 hours by peritoneal cells isolated from mice treated with BRMs.…

MalePathologymedicine.medical_specialtyPolymersPyran Copolymermedicine.medical_treatmentImmunologySpleenAdenocarcinomaToxicologyMicePeritoneal cavitymedicineAnimalsBiological response modifiersPeritoneal NeoplasmsPharmacologyMice Inbred BALB CChemotherapybusiness.industryCancerImmunotherapymedicine.diseaseKidney NeoplasmsKiller Cells NaturalSerous fluidmedicine.anatomical_structureDoxorubicinInterleukin-2FemaleImmunotherapyLymphbusinessJournal of Immunopharmacology
researchProduct

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A co…

2020

Abstract Background Expression of proton-coupled folate transporter (PCFT) is associated with survival of mesothelioma patients treated with pemetrexed, and is reduced by hypoxia, prompting studies to elucidate their correlation. Methods Modulation of glycolytic gene expression was evaluated by PCR arrays in tumour cells and primary cultures growing under hypoxia, in spheroids and after PCFT silencing. Inhibitors of lactate dehydrogenase (LDH-A) were tested in vitro and in vivo. LDH-A expression was determined in tissue microarrays of radically resected malignant pleural mesothelioma (MPM, N = 33) and diffuse peritoneal mesothelioma (DMPM, N = 56) patients. Results Overexpression of hypoxia…

MesotheliomaCancer ResearchPleural NeoplasmsCell Culture TechniquesPemetrexedDeoxycytidineArticle03 medical and health sciencesMice0302 clinical medicinelactate dehydrogenase inhibitorsIn vivoAntigens NeoplasmCell Line TumormedicineGene silencingAnimalsHumansMesotheliomaEnzyme InhibitorsCarbonic Anhydrase IXPeritoneal Neoplasms030304 developmental biology0303 health sciencesL-Lactate DehydrogenaseCell growthChemistryhypoxiaMesothelioma MalignantDrug SynergismHypoxia (medical)Translational researchmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaXenograft Model Antitumor AssaysGemcitabineGemcitabineCell HypoxiaGene Expression Regulation NeoplasticPemetrexedOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisPeritoneal mesotheliomaCancer researchFemalemedicine.symptomProton-Coupled Folate Transportermedicine.drugBritish journal of cancer
researchProduct

Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma

2016

A series of 22 derivatives of the [1,2]oxazolo[5,4-e]isoindole system were synthesized through an efficient and versatile procedure that involves the annelation of the [1,2]oxazole moiety to the isoindole ring, producing derivatives with a wide substitution pattern. The structure-activity relationship indicates that the N-4-methoxybenzyl group appears crucial for potent activity. In addition, the presence of a 6-phenyl moiety is important and the best activity is reached with a 3,4,5-trimethoxy substituent. The most active compound, bearing both the structural features, was able to inhibit tumor cell proliferation at nanomolar concentrations when tested against the full NCI human tumor cell…

MesotheliomaLung NeoplasmsMice NudeAntineoplastic AgentsApoptosisIsoindoles01 natural sciencesMiceStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoDrug DiscoveryTumor Cells CulturedAnimalsHumansMoietyPeritoneal NeoplasmsCell ProliferationOxazoleDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryCell growthMedicine (all)Drug Discovery3003 Pharmaceutical ScienceCell CycleMesothelioma MalignantNeoplasms ExperimentalSettore CHIM/08 - Chimica FarmaceuticaIn vitro0104 chemical sciencesMedicine (all); Molecular Medicine; Drug Discovery3003 Pharmaceutical ScienceBiochemistryApoptosisCell culture030220 oncology & carcinogenesisMolecular MedicineDrug Screening Assays AntitumorIsoindoleJournal of Medicinal Chemistry
researchProduct

Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models.

2013

In this study, we describe the synthesis of new nortopsentin analogues, 1H-pyrrolo[2,3-b]pyridine derivatives and their biological effects in experimental models of diffuse malignant peritoneal mesothelioma (DMPM), a rare and rapidly fatal disease, poorly responsive to conventional therapies. The three most active compounds, 1f (3-[2-(5-fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-b]pyridine), 3f (3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-b]pyridine), and 1l (3-[2-(5-fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-b] pyridine), which were shown to act as cyclin-dependent kinase 1 inhibitors, consistently reduced DMPM cell prol…

MesotheliomaMagnetic Resonance SpectroscopyCell growthKinasePyridinesAntineoplastic AgentsPharmacologyCell Linechemistry.chemical_compoundchemistryPaclitaxelApoptosisCell cultureDrug DiscoveryPyridineSurvivinMolecular MedicineCytotoxic T cellHumansSpectrophotometry UltravioletPeritoneal NeoplasmsJournal of medicinal chemistry
researchProduct

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer

2019

BACKGROUND: TNM stage has been identified as an independent variable for local recurrence and survival after colon cancer resection. It is still unclear whether peritoneal invasion (pT4a) is a risk factor for adverse oncologic outcome or whether these patients have better results compared with contiguous organs infiltration (pT4b), independent from nodal status (pN). OBJECTIVE: The purpose of this study was to analyze whether peritoneal invasion is an independent risk factor for worse oncologic outcome after curative colon cancer resection. DESIGN: This was a retrospective analysis with multivariate regression of a prospective database, according to Strengthening the Reporting of Observatio…

OncologyMalemedicine.medical_specialtySurvivalColorectal cancermedicine.medical_treatmentLocally advancedT stageLocally advanced colon cancer03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineColon cancer resectionHumansNeoplasm InvasivenessRisk factorStage (cooking)Survival rateColectomyPeritoneal NeoplasmsColectomyAgedNeoplasm StagingRetrospective StudiesCarcinomatosisTumor-node-metastasisbusiness.industryGastroenterologyRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasePrognosisColon cancerSurvival RateTreatment Outcome030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence Localbusiness
researchProduct